BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:RC148 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of RC148\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07462143-2698@assetmemo.bio
DTSTAMP:20261121T004539Z
DTSTART;VALUE=DATE:20270512
DTEND;VALUE=DATE:20270513
SUMMARY:RC148: Phase 2/3 readout est. (NCT07462143)
DESCRIPTION:RC148\, phase 2/3.\nStudy: A Phase Ⅱ/Ⅲ Clinical Trial of RC
 148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorec
 tal Cancer\nEstimated primary completion: 12 May 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/rc148#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07462143
URL:https://assetmemo.bio/drug/rc148#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07874282-2698@assetmemo.bio
DTSTAMP:20261121T004539Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:RC148: Phase 2 readout est. (NCT07874282)
DESCRIPTION:RC148\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Phase II 
 Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148(ABBV-
 1480) as First-Line Treatment for Patients With Non-Squamous Non-Small-Cel
 l Lung Cancer\nEstimated primary completion: December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/rc148#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07874282
URL:https://assetmemo.bio/drug/rc148#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07416474-2698@assetmemo.bio
DTSTAMP:20261121T004539Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:RC148: Phase 3 readout est. (NCT07416474)
DESCRIPTION:RC148\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: RC148 Plu
 s Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemothe
 rapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)\nEstimat
 ed primary completion: 31 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/rc148#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07416474
URL:https://assetmemo.bio/drug/rc148#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895355-2698@assetmemo.bio
DTSTAMP:20261121T004539Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:RC148: Phase 2 readout est. (NCT07895355)
DESCRIPTION:RC148\, phase 2.\nStudy: Phase II Clinical Study of RC148 (ABBV
 -1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemo
 therapy) for Unresectable Colorectal Cancer\nEstimated primary completion:
  July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rc148#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0789535
 5
URL:https://assetmemo.bio/drug/rc148#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07756645-2698@assetmemo.bio
DTSTAMP:20261121T004539Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:RC148: Phase 3 readout est. (NCT07756645)
DESCRIPTION:RC148\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Study t
 o Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembroliz
 umab Combined With Chemotherapy for the First Line Treatment of Locally Ad
 vanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants\nEstima
 ted primary completion: December 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/rc148#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07756645
URL:https://assetmemo.bio/drug/rc148#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07935369-2698@assetmemo.bio
DTSTAMP:20261121T004539Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:RC148: Phase 2/3 readout est. (NCT07935369)
DESCRIPTION:RC148\, phase 2/3.\nStudy: RC118 Combined With RC148 as First-L
 ine Treatment for Claudin 18.2-Positive\, HER2-Negative Advanced G/GEJ Ade
 nocarcinoma\nEstimated primary completion: 30 April 2030. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/rc148#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07935369
URL:https://assetmemo.bio/drug/rc148#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07829549-2698@assetmemo.bio
DTSTAMP:20261121T004539Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:RC148: Phase 3 readout est. (NCT07829549)
DESCRIPTION:RC148\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Phase III
  Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as
  First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without 
 Actionable Genomic Alterations\nEstimated primary completion: April 2031. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/rc148#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07829549
URL:https://assetmemo.bio/drug/rc148#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
